EMA Recommends Extension of Therapeutic Indications for Niraparib / Abiraterone Acetate By Ogkologos - February 20, 2026 75 0 Facebook Twitter Google+ Pinterest WhatsApp New combination concerns a combination with ADT for the treatment of adult patients with mHSPC and BRCA1/2 mutations Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Nivolumab with Chemotherapy for Previously Untreated Hodgkin Lymphoma 2026 ESMO Breast Cancer Award Recipient Announced Solid Organ Transplant Recipients with Pretransplant Cancer Have an Elevated Risk of Posttransplant Cancer of the Same Cancer Type MOST POPULAR Antitumour Activity of Combination of Lenvatinib and Pembrolizumab in Patients with... August 2, 2022 Longitudinal Molecular Profiling of CTCs Captures New Insights in mRCC June 1, 2022 Adding Tremelimumab to Durvalumab and Chemotherapy Provides Survival Benefit for Patients... November 15, 2022 ¿Puede el uso de un microondas causar cáncer? April 7, 2022 Load more HOT NEWS Los ensayos clínicos y las personas mayores, con Dr. Enrique Soto FDA Approves Daratumumab and Hyaluronidase-fihj with Bortezomib, Lenalidomide, and Dexamethasone for... Research with integrity – all the fun of the FAIR What to Do When You Are Diagnosed With Cancer During Pregnancy
